ARTICLE | Company News
Amicus prices Galafold at $315k per year
August 13, 2018 7:53 PM UTC
Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation.
On Friday, FDA granted accelerated approval to Galafold to treat Fabry disease in adults with amenable mutations. Amicus said the U.S. approval is the first for a new Fabry disease therapy in more than 15 years (see "Amicus' Galafold Wins Accelerated Approval from FDA")...
BCIQ Company Profiles
BCIQ Target Profiles